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dysplasia. Methods We report the case of a 32-year-old patient with recurrent genital dysplasia under
long-term therapy for CD with a focus on different drug-related, immunosuppressive mechanisms. Results
Gynecological examination and biopsy revealed high-grade vulvar intraepithelial neoplasia (VIN) positive
for HPV 16 treated with laser vaporization. Due to the combination of HPV positivity, intraoperative
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Abstract
Background: Young patients with Crohn’s disease (CD) 
show a high prevalence of human papillomavirus (HPV) 
which is the main cause of high-grade squamous intraepi-
thelial lesions (HSIL). A major complication for patients un-
dergoing immunocompromising therapy is the develop-
ment of genital dysplasia. Methods: We report the case of a 
32-year-old patient with recurrent genital dysplasia under 
long-term therapy for CD with a focus on different drug-re-
lated, immunosuppressive mechanisms. Results: Gyneco-
logical examination and biopsy revealed high-grade vulvar 
intraepithelial neoplasia (VIN) positive for HPV 16 treated 
with laser vaporization. Due to the combination of HPV pos-
itivity, intraoperative multilocularity, and CD, follow-up ex-
aminations were performed every 6 months. One year later, 
the patient showed a VIN at a new location and additionally, 
a cervical intraepithelial neoplasia (CIN), which were surgi-
cally treated. Catch-up HPV vaccination was applied acces-
sorily. After the switch from a TNF-α blocker to vedolizumab, 
which acts as a gut-selective anti-integrin, the subsequent 
PAP smear, vulvoscopy, and colposcopy showed no more 
evidence of dysplasia. Conclusions: This case report high-
lights that gut-selective immunosuppression with vedoli-
zumab might be favorable in young HPV-positive patients 
due to a good side effect profile. Regular screening and HPV 
vaccination are a mainstay of dysplasia prevention and con-
trol. The risk for HPV-associated dysplasia in immunosup-
pressed patients is highly dependent on the choice of im-
munosuppressive therapy. © 2019 S. Karger AG, Basel
Introduction
Around 80% of sexually active adults will acquire a hu-
man papillomavirus (HPV) infection at least once in their 
lifetime. The highest prevalence of HPV infection in the 
female genital tract (up to 30%) is found in 15 to 25-year-
old females due to a low immunization rate and the fre-
quent switching of sexual partners relative to older age 
groups [1–3]. HPV is associated with several genital ma-
lignant cancer precursors including cervical intraepithe-
lial neoplasia (CIN), vulvar intraepithelial neoplasia 
(VIN), vaginal intraepithelial neoplasia (VAIN), and anal 
intraepithelial neoplasia (AIN). These precancerous le-
sions are differentiated into low- and high-grade squa-
mous intraepithelial lesions (LSIL, HSIL) [4–6]. The host 
immune system usually clears an HPV infection success-
fully.
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Patients with immunosuppressive drugs have an in-
creased risk for persistent infections and progression to 
intraepithelial neoplasia [7]. The neoplasia risk differs 
depending on both the underlying disease and the mech-
anism of action of the immunosuppressant. In Crohn’s 
disease (CD), which is one of the two main forms of in-
flammatory bowel disease, currently used immunosup-
pressive therapies include glucocorticosteroids, metho-
trexate, thiopurines, and biologicals. The most frequent-
ly used biologicals are tumor necrosis factor (TNF)-α 
blockers, ustekinumab and vedolizumab. Vedolizumab 
is a fully humanized monoclonal antibody that specifi-
cally blocks the migration of a subset of leukocytes har-
boring the αβ47 integrin into inflamed intestinal tissue 
via MAdCAM-1. Those biologicals which work against 
cytokines or cell surface antigens are very potent thera-
peutics against autoimmune diseases, inflammatory dis-
eases, and tumors. However, these biologicals can also 
induce adverse reactions including autoimmunity as 
well as bacterial, viral, or fungal infections [8, 9]. Pa-
tients with HPV infection and inflammatory bowel dis-
ease have an increased prevalence for genital dysplasia 
[10–14].
We aim to raise awareness of immunosuppression-as-
sociated and HPV-induced genital dysplasia and discuss 
possible pathomechanisms.
Materials and Methods
We describe the case of a 32-year-old female patient who was 
diagnosed with CD at the age of 22 years. We consider the patient’s 
history, the course of the disease with a focus on the occurrence of 
genital dysplasia, and the clinical findings in colposcopy and his-
tology. Different conservative and surgical treatments are dis-
cussed, with a focus on the role of the immunosuppressive side 
effects of the currently used biologicals. Recommendations for the 
follow-up care and disease management for young, female patients 
with CD are derived from both the presented clinical findings and 
from a review of the literature. 
Results
The 32-year-old patient had a 10-year history of CD 
and presented with unilateral vulvar edema 8 years after 























































Fig. 1. Occurrence of HPV-associated dysplasia depending on the drug intake. The x axis shows the timeline in 
years of age and chronological use of immunosuppressants, as well as the drug effect in a semiquantitative way 
from – (no effect) to +++ (maximum effect). The y axis demonstrates vulvar and cervical dysplasia. Outlines of 
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a terminal ileitis, left-sided colitis, and perianal activity. 
For the first 5 years following the diagnosis, the patient 
received several immunosuppressive agents including 
glucocorticosteroids, thiopurines (short-term for 3–4 
weeks in the first and fifth year of the disease; not toler-
ated due to adverse events such as headache, nausea, and 
arthralgia), and TNF-α blockers including 2 years of inf-
liximab treatment, 2 years of adalimumab treatment, and 
3 months of certolizumab pegol treatment (Fig. 1). Due 
to a steroid-refractory ileus, a laparoscopic ileocecal re-
section was performed at age 27 with postoperative com-
plications. The recovery after the laparoscopic ileocecal 
resection was complicated due to anastomotic leakage of 
the ileo-transverse anastomosis, a fistula of the small 
bowel 50 cm after the angle of Treitz, a stomal stenosis, 
and an abscess in the right lower abdomen requiring two 
subsequent laparotomies. Due to an early CD relapse, go-
limumab was given as a fourth TNF-α blocker for 2 years 
(which it must be stated is an off-label treatment since 
golimumab is licensed for ulcerative colitis only). After 8 
years of CD and after years of immunosuppression in-
cluding thiopurines and four different TNF-α blockers, 
the patient developed a swelling of the left labium majus. 
An MRI showed no evidence of underlying fistulizing CD 
or granulomatous subcutaneous disease. The patient was 




Fig. 2. Vulvoscopic and colposcopic presentation of different types of genital dysplasia in our patient. a Edema 
of the left labium majus. b Aceto-white leukoplakia of the left labium minus, histologically VIN III. c Aceto-white 
(5%) leukoplakia of the perineum, histologically VIN III. d Lesion after excision and laser evaporization. e Col-
poscopy of the cervical lesion; biopsy revealed an HSIL at 2 o’clock. f Cervical lesion (close-up); aceto-white pat-
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intercourse in a stable relationship. The patient was ad-
mitted to the gynecological outpatient clinic to rule out 
an immunosuppression-associated complication (infec-
tion or cancer). There was no evidence of an infectious 
disease. The size of the edema was demarcated by the left 
labium majus, and measured approximately 7.8 × 3.2 × 
0.4 cm (Fig. 2a). A vulvo-colposcopy was performed with 
the application of aqueous 5% acetic acid (Fig.  2b). A 
punch biopsy of the left labium minus was taken from an 
aceto-positive discrete keratosis that histologically 
showed a high-grade lesion (VIN III), which was HPV 16 
positive (Fig. 2b). In this examination, the VIN was de-
tected as an incidental finding but as a potentially malig-
nant disease. No biopsy was undertaken from the soft, 
smooth, and even edema, as no genital granulomatosis 
was clinically suspected in the pelvic MRI. Elephantiasis 
with filarial parasites did not align with the personal his-
tory. As the edema was self-limiting and did not recur, no 
further edema-specific examinations were considered 
necessary.
A lymphedema of the left labium majus was postulated 
due to several abdominal surgeries (Fig.  2a). However, 
the last abdominal surgery (a colonic resection of the 
transverse colon and a reversal of an ileal stoma) had been 
performed 3 years previously. 
In the subsequent surgery, VIN III was intraopera-
tively excised on both sides of the labium minus, and a 
biopsy in the introitus revealed a further low-grade intra-
squamous lesion (VIN I, LSIL). Histological examination 
showed dysplasia-free margins (R0). Laser vaporization 
of the surroundings of the vulvar lesions and introital 
biopsy were performed. The immunosuppression with 
golimumab as a fourth TNF-α blocker was continued 
due to the lack of alternatives at that time. The follow-up 
examination after 6 months was unremarkable. Another 
6 months later, the follow-up examination showed a 
high-grade VIN (VIN II–III) lesion at the left labium ma-
jus, in the posterior part, without edema (Fig. 2c). There-
fore, a fusiform excision of the left labium major, a peri-
neal biopsy, laser vaporization of the vulva, a punch bi-
opsy of the cervix, and an anoscopy were carried out 
(Fig. 2d).
Histology of the cervix also revealed an HSIL (Fig. 2e, 
f), that was removed by the loop electrosurgical excision 
(LEEP) procedure. Additionally, an HPV catch-up vac-
cination with the quadrivalent agent Gardasil was admin-
istered [15]. At that time, the immunosuppressive agent 
was switched to vedolizumab as a gut-selective immuno-
suppressive agent, which had newly become available in 
Switzerland. 
Follow-up examinations carried out over the follow-
ing 21 months, and while using the vedolizumab-based 
treatment, showed no further abnormalities in either 
the PAP smears or in the aceto-white testing. At age 32, 
and 1.5 years after the first VIN treatment, the patient 
became pregnant. After two miscarriages, both in the 
first trimester, the third pregnancy took an obstetrical-
ly normal course. Colposcopic and cytological exami-
nations did not reveal any dysplasia. Continued treat-
ment with vedolizumab and mesalazine before preg-
nancy and in the first trimester of pregnancy could not 
prevent a small intestinal ileus due to fibrostenotic CD. 
A second small intestinal resection (17.5 cm) with post-
operative anastomotic leakage and ileostomy was per-
formed in the second trimester. Despite all the medica-
tion and surgical complications, the patient delivered 
a healthy baby in the 37th gestational week (2,770 g, 
46 cm).
Discussion
CD is a chronic inflammatory bowel disease affecting 
young patients [16]. CD often coincides with the fertile 
phase which is also the most vulnerable phase for HPV 
infections [3]. This case study supports previous studies 
that highlighted the role of immunosuppressive agents in 
the development of multilocular genital dysplasia in CD 
patients [17–19], while providing new insight into the 
beneficial role of a gut-selective immunosuppression 
therapy.
CD itself may be associated with a greater risk of geni-
tal dysplasia, especially for VIN [12, 18]. Immunosup-
pressive treatments, which are necessary in most patients, 
may additionally have an impact on infection risk and 
HPV progression. Azathioprine increases the risk of gen-
ital dysplasia in a dose-dependent manner [20]. In our 
patient the high-grade lesions occurred under long-
standing therapy with different TNF-α blockers (Fig. 2). 
Genital dysplasia has been described after the use of 
TNF-α blockers [21, 22]. TNF-α plays an important role 
in the immune response to infections. After application 
of anti-TNF-α monoclonal antibodies, activated T lym-
phocytes and macrophages fall into apoptosis in vivo [23–
25]. Literature concerning HPV infections under TNF-α 
blockers is scarce. However, it has been shown that HPV-
specific CD4+ and CD8+ T cells are important for long-
term tumor protection [26]. We assume that the immu-
nosuppression played an important role in the rapid pro-
gression of the condition to genital high-grade dysplasia 
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at a young age and to the de novo occurrence of high-
grade lesions at different sites.
The most interesting finding of our case, however, is 
that the HPV-associated precancerous lesions disap-
peared in a follow-up performed 2 years after the switch 
from unselective immunosuppression with TNF-α block-
ers to the gut-selective antibody vedolizumab. Careful 
follow-up controls with PAP smears and vulvo-colposco-
py including aceto-white testing were normal. Vedoli-
zumab shows a strong or intense binding capacity to the 
small intestine and colon, respectively, as the main targets 
for CD treatment [27, 28], but no or only a weak binding 
capacity to the skin (vulva) and the cervix, respectively 
[20]. Our findings suggest that, in the context of genital 
dysplasia, it is favorable to use either inflammatory bow-
el disease treatments that are less immunosuppressive 
(avoiding TNF-α blockers) or specific immunosuppres-
sive treatments (including the gut-selective antibody ve-
dolizumab).
Other potentially relevant risk factors for a more rapid 
disease progression are age over 25 years, HSIL of the cer-
vix, and a history of an HPV type 16 infection [29]. The 
occurrence and recurrence of genital dysplasia in our case 
were certainly influenced by these different risk factors. 
Routine PAP smears are performed every 3 years in the 
base Swiss population. In the context of female CD pa-
tients, the ECCO guidelines strongly recommend regular 
gynecologic screening for cervical cancer, especially if the 
patient is also being treated with immunosuppressive/
immunomodulating drugs. Our case highlights that gy-
necologic screening in CD patients should include careful 
vulvoscopy to exclude VIN as well. We propose an an-
nual screening for CD patients (PAP smear plus HPV 
PCR) as well as a vulvo-colposcopy of the anogenital re-
gion with aceto-white testing for the early detection of 
anogenital lesions. In the case of posttreatment, we pro-
pose follow-up visits every 6 months.
The initial vulvar edema was self-limiting in our pa-
tient. In the literature the underlying pathomechanism of 
vulvar edema is described as a chronic granulomatous in-
flammation of the skin which is one of the extra-intestinal 
manifestations of CD [30]. However, histologies in our 
patient showed no evidence of dermal epithelioid granu-
lomas.
Based on the gynecological findings and locations, as 
seen in Figure 1, the treatment had to be individually ad-
justed since laser vaporization, excision, and conization 
have different risk profiles. To find the suitable treatment 
choice, the staging of the lesion, the age of the patient, and 
the cytology should all be considered [31]. 
For instance, cervical conization needs to be highlighted 
in the context of this case, since our patient had a desire to 
become pregnant. This is due to the fact that the height of 
the conus has a major impact on the risk of preterm deliv-
ery. A significant increase for preterm delivery was found 
at a conus height of 1.5 cm. The LEEP procedure showed 
the best outcome (lowest risk) regarding a preterm delivery 
and is therefore the gold standard [32, 33]. Standard prac-
tice in preconception counseling after a conization with 
dysplasia-free margins (R0) is to defer pregnancy for 6 
months in order to prove a negative PAP smear. 
The additional quadrivalent HPV vaccination after the 
conization was performed to improve the outcome after 
the different surgical treatments and also to improve the 
patient’s immunity. The determinant factor for this ap-
proach is a proven lower relapse rate of about 35.2% [34]. 
Vaccination might have contributed to the favorable fol-
low-up. There are three currently available vaccines: di-
valent targeting HPV 16/18, quadrivalent targeting HPV 
6/11/16/18, and nonvalent targeting the aforementioned 
types as well as HPV types 31/33/45/51/58. The vaccines 
demonstrated a potential to prevent 70% of cervical can-
cer within an adequately vaccinated population. In the 
future, it is expected that the nonvalent vaccines achieve 
an 85–95% protection against VIN and a 90% protection 
against CIN [35, 36]. The American Society for Colpos-
copy and Cervical Pathology (ASSCP) recommends that 
the most effective primary prevention is to vaccinate girls 
before they become sexually active [37].
A better understanding of the pathways of HPV infec-
tion and immunity is crucial in order to be able to develop 
individualized recommendations. Given the fact that there 
is still a knowledge gap, HPV vaccination of immunocom-
promised patients and patients with an iatrogenic immu-
nocompromising therapy is crucial. Various immunosup-
pressive agents including biologicals have to be followed 
meticulously regarding their effects on genital dysplasia in 
order to prevent cervical, vulvar, vaginal, or anal cancer.
Conclusion
Our case study demonstrated the recurrence of HPV-
associated multilocular genital dysplasia under TNF-α 
blockers. The genital dysplasia was detected due to a good 
collaboration between different medical specialties. The 
early detection in combination with an individualized 
therapy including surgery, vaccination, and adjustment 
of immunosuppression therapy led to a favorable out-
come.
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